OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

News

OCRFA Founder Sol Schreiber passes away

(6/9/16) With deep sorrow, Ovarian Cancer Research Fund Alliance mourns the passing of our beloved founder and Chairman Emeritus, Sol Schreiber. We are profoundly grateful for his foresight in founding this organization, as well as his unwavering leadership through the years. His steady commitment to... 

OCRFA Research Shows Genetic Subtypes Linked to Increased Risk of Ovarian Cancer

Kunle Odunsi, MD, PhD (June 9, 2016) A ten year, OCRFA-funded study has revealed the effect that the human leukocyte antigen (HLA) genes, which help regulate the body’s immune system, have on how the body responds to treatment of epithelial ovarian cancer. The scientists report that women with certain... 

Risk Factors and Outcomes for Chemotherapy Refusal

(June 7, 2016) The Journal of the National Comprehensive Cancer Network recently published a study that looked at the difference in outcomes between two groups of epithelial ovarian cancer patients: those who received recommended, multiagent chemotherapy and those who chose not to undergo the recommended... 

The Impact of BMI on IP Therapy

(May 25, 2016) A new study published in the International Journal of Gynecological Cancer earlier this month investigated the impact of body mass index (BMI) on completion, complications, and clinical outcomes of intraperitoneal (IP) chemotherapy in patients with advanced-stage ovarian cancer. The study... 

Action Alert: Protect Ovarian Cancer Research Funding at the Department of Defense

Later this week, we’ll be sending out a request for you to take Action to help protect ovarian cancer research funding at the Department of Defense. The Ovarian Cancer Research Program (OCRP) is part of the Congressionally Directed Medical Research Program in the Department of Defense (DoD), and funds... 

Newk’s Unites 100 Restaurants to Raise $100,000 for Ovarian Cancer Research

Foodie Fast-Casual Brand Reaches Halfway Point in Its 200-Unit Growth Plan JACKSON, Miss. — Pairing a big moment with a big cause, fast-casual Newk’s Eatery is celebrating its centennial restaurant opening by uniting system-wide to raise $100,000 for ovarian cancer research starting April 4. Each... 

OCRFA Research Helps Explain Resistance to Chemotherapy

Weiping Zou, MD, PhD (May 4, 2016) Research funded in part by an OCRFA research grant to Dr. Weiping Zou at the University of Michigan has shown that the sensitivity and resistance to cancer chemotherapies is not fully explained by genomic mechanisms as it has previously thought.  In fact, it may be... 

Irregular Periods May Increase Ovarian Cancer Risk

(May 2, 2016) Research published last month in the International Journal of Cancer showed an unexpected finding: young women with irregular menstrual periods may be at higher risk of developing—and dying from—ovarian cancer later in life. The study provides the first evidence linking abnormally long... 

Stand Up To Cancer Supports “Innovation in Collaboration” in Cancer Research with $1 Million for Five Teams through Phillip A. Sharp Awards

May 2, 2016 – Stand Up To Cancer (SU2C) has awarded a total of $1 million to five teams of cancer researchers to advance “innovation in collaboration” among SU2C-­‐affiliated scientists. Each team, consisting of researchers from different SU2C-­‐supported “Dream Teams” or research programs,... 

Hormone Therapy Safe After Nonserous Ovarian Cancer

(April 25, 2016) New findings published online this month in Obstetrics and Gynecology suggest that hormone therapy (HT) can be used safely to manage menopausal symptoms in women who have undergone treatment for nonserous epithelial ovarian cancer. The study showed no reduction in overall survival with...